GPs being sent warning letters and the World Health Organization’s World Vaccinations Week have brought the spectre of antimicrobial resistance (AMR) back into the headlines of late.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh